{"entity":{"id":"bmt-ctn-1102","kind":"trial","name":"BMT CTN 1102","aka":["BMTCTN1102","CTN 1102"],"tldr":"BMT CTN 1102 settled whether older people with higher-risk myelodysplastic syndrome should be offered a stem-cell transplant: those who had a matched donor and went to transplant were far more likely to be alive three years later than those without a donor who had drug treatment instead, so transplant belongs in the plan for fit patients aged 50 to 75.","summary":"BMT CTN 1102 was a multicentre biologic assignment trial of the Blood and Marrow Transplant Clinical Trials Network in 384 patients aged 50 to 75 with intermediate-2 or high-risk de novo myelodysplastic syndrome enrolled at 34 centres between 2014 and 2018. Patients were assigned to the donor arm (reduced-intensity allogeneic transplant) or the no-donor arm (hypomethylating therapy or best supportive care) according to whether a matched donor was found within 90 days of registration. The primary endpoint was overall survival at three years by intention to treat.\n\nAdjusted three-year overall survival was 47.9 percent in the donor arm against 26.6 percent in the no-donor arm, an absolute difference of 21.3 percentage points, and leukaemia-free survival was 35.8 against 20.6 percent; the benefit held across every subgroup examined. The trial is the evidence that reduced-intensity transplant should be an integral part of management for fit older adults with higher-risk disease, which is how the corpus's myelodysplastic syndrome page cites it.","status":"positive","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT02016781","url":"https://clinicaltrials.gov/study/NCT02016781"}],"tags":["soc-trials"],"related":[],"cancers":["mds-higher-risk","mds"],"sections":[],"technologies":["allogeneic-hsct","epigenetic-drugs"],"targets":[],"drugs":["azacitidine"],"companies":[],"institutions":["mcw-cancer-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-bmt-ctn-1102-transplant-older-mds-nakamura-jco-2021"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02016781","phase":"2","setting":"Intermediate-2 or high-risk de novo myelodysplastic syndrome in patients aged 50 to 75: assignment by donor availability within 90 days to reduced-intensity allogeneic transplant or to hypomethylating therapy or best supportive care, with three-year overall survival as the primary endpoint","sponsor":"Medical College of Wisconsin","result":"Three-year overall survival 47.9 percent with a donor and reduced-intensity transplant against 26.6 percent without a donor (p 0.0001); leukaemia-free survival 35.8 against 20.6 percent.","yearReported":2021,"enrolled":384,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall survival at 3 years (intention to treat, adjusted)","primary":true,"unit":"%","arms":[{"name":"Donor arm: reduced-intensity allogeneic transplant","value":47.9,"note":"95% CI 41.3 to 54.1"},{"name":"No-donor arm: hypomethylating therapy or best supportive care","value":26.6,"note":"95% CI 18.4 to 35.6"}],"p":"0.0001","source":"https://doi.org/10.1200/JCO.20.03380"},{"endpoint":"Leukaemia-free survival at 3 years","unit":"%","arms":[{"name":"Donor arm: reduced-intensity allogeneic transplant","value":35.8,"note":"95% CI 29.8 to 41.8"},{"name":"No-donor arm: hypomethylating therapy or best supportive care","value":20.6,"note":"95% CI 13.3 to 29.1"}],"p":"0.003","source":"https://doi.org/10.1200/JCO.20.03380"}]},"route":"/trials/bmt-ctn-1102/","neighbours":{"cancer":[{"id":"mds-higher-risk","kind":"cancer","name":"Higher-risk myelodysplastic syndromes","route":"/cancers/mds-higher-risk/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"technology":[{"id":"allogeneic-hsct","kind":"technology","name":"Allogeneic stem cell transplantation","route":"/technologies/allogeneic-hsct/"},{"id":"epigenetic-drugs","kind":"technology","name":"Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)","route":"/technologies/epigenetic-drugs/"}],"drug":[{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/"}],"institution":[{"id":"mcw-cancer-center","kind":"institution","name":"Medical College of Wisconsin Cancer Center","route":"/institutions/mcw-cancer-center/"}],"paper":[{"id":"paper-bmt-ctn-1102-transplant-older-mds-nakamura-jco-2021","kind":"paper","name":"BMT CTN 1102: biologic assignment trial of reduced-intensity transplant by donor availability in patients aged 50 to 75 with advanced myelodysplastic syndrome","route":"/key-papers/paper-bmt-ctn-1102-transplant-older-mds-nakamura-jco-2021/"}]}}